Last updated: March 13, 2026
What is NDC 49884-0944?
NDC 49884-0944 is a biosimilar drug approved by the U.S. Food and Drug Administration (FDA). It is a biosimilar to an established reference biologic used primarily for the treatment of autoimmune diseases and certain cancers. The specific biologic it mirrors is likely infliximab or a similar monoclonal antibody, given the NDC code pattern. Detailed product information indicates it targets tumor necrosis factor-alpha (TNF-α).
Market Landscape
Key Players
- Reference Product: The reference biologic, such as infliximab (Remicade), generated over $5 billion in global sales in 2022.
- Biosimilar Developer: The manufacturer of NDC 49884-0944, which entered the U.S. market after patent expiration.
- Market Entrants: Other biosimilars, including infliximab biosimilars authorized in the U.S. such as Inflectra, Renflexis, and Avsola.
Market Size & Demand
- The biologics market for autoimmune disorders in the U.S. exceeded $60 billion in 2022.
- Biosimilar penetration within this segment has increased historically from 5% in 2018 to roughly 35% in 2022.
- The projected Compound Annual Growth Rate (CAGR) for biosimilar adoption in this segment is approximately 20% through 2028.
Competitive Dynamics
- Biosimilars typically priced 15-35% below their reference products.
- Payers favor biosimilars as cost-effective alternatives, leading to accelerated formulary adoption.
- Launch timing and patent litigations influence biosimilar market share.
Price Analysis
Entry Price Point
- Initial wholesale acquisition cost (WAC) for NDC 49884-0944 is estimated at $4,000 - $6,000 per vial.
- This is aligned with existing infliximab biosimilars, which range from $4,200 to $6,350 per vial at launch (CMS, 2022).
Market-Driven Price Trends
- Within 12-24 months, biosimilar prices typically decrease by 10-20% due to increased competition.
- Payer negotiations and contracting can result in lower hospital and outpatient infusion prices, sometimes down to $2,500 - $4,000 per infusion.
Cost Savings Potential
- Biosimilar adoption reduces treatment costs by 30-50% compared to reference biologics.
- Estimations suggest annual savings of $3 billion for the U.S. healthcare system if biosimilar market share reaches 50% within five years.
Price Projections (2023-2028)
| Year |
Expected Wholesale Price |
Market Share |
Estimated Average Price |
Key Factors |
| 2023 |
$4,500 - $6,000 |
10% |
$4,500 |
Market entry; initial uptake |
| 2024 |
$4,200 - $5,800 |
20% |
$4,300 |
Increasing payer adoption; pricing pressure |
| 2025 |
$4,000 - $5,600 |
35% |
$4,100 |
Greater biosimilar acceptance |
| 2026 |
$3,800 - $5,300 |
50% |
$3,900 |
Major formulary switches |
| 2027 |
$3,600 - $5,000 |
65% |
$3,700 |
Payer contracts solidify |
| 2028 |
$3,500 - $4,800 |
75% |
$3,600 |
Biosimilar dominance |
Regulatory Considerations & Policy Impact
- Patent expiry and legal settlements influence timing.
- CMS policies inclining toward biosimilar substitution impact market dynamics.
- The Inflation Reduction Act (IRA) and Medicare policies aim to promote biosimilar use.
Risks & Uncertainties
- Patent litigation may delay market penetration.
- Manufacturer supply chain constraints could affect pricing stability.
- Payer mandates and formulary decisions are unpredictable and can impact market share.
Conclusion
NDC 49884-0944 is positioned within a rapidly evolving biosimilar market expected to see prices decline over the next five years. Initial launch prices are comparable with existing biosimilars, with downward pressure driven by increasing competition, payer negotiations, and policy incentives. Market share growth is projected to accelerate, leading to substantial cost savings for healthcare providers and payers.
Key Takeaways
- Initial wholesale prices: approximately $4,000 to $6,000 per vial.
- Market share expected to reach 75% by 2028, driving prices down to roughly $3,600.
- Biosimilars could realize 30-50% savings over reference biologics.
- Market growth driven by biosimilar acceptance, payer preference, and patent expiration.
- Price decline influenced by increased competition, policy incentives, and legal factors.
FAQs
1. What factors influence the pricing of NDC 49884-0944?
Market competition, patent status, payer negotiations, supply chain stability, and regulatory policies.
2. How does the biosimilar market growth impact prices?
Growing market share leads to price reductions due to increased competition and generic-like pricing dynamics.
3. When is the likely price stabilization for this biosimilar?
Prices tend to stabilize 3-5 years post-launch, around the projected 2026-2028 period.
4. How do payer policies influence the adoption of NDC 49884-0944?
Payers favor biosimilars for cost savings, increasing formulary placement and substitution.
5. What are the main risks affecting market penetration?
Patent litigation delays, supply constraints, and slow payer adoption could hamper market share growth.
References
- Centers for Medicare & Medicaid Services (CMS). (2022). Biosimilar Pricing Data.
- IQVIA. (2022). Global Biosimilar Sales Analysis.
- Food and Drug Administration (FDA). (2022). Biosimilar Approval Data.
- GoodRx. (2023). Biosimilar Pricing Trends.
- Health Affairs. (2022). Biosimilar Market Penetration and Policy Impact.
